CVS said at the March 5, 2024 investor meetings and webcast that its senior management team will reaffirm its previously announced full-year 2024 GAAP diluted earnings per share (EPS) guidance of at least $7.06 and Adjusted EPS guidance of at least $8.30.

1. 01

   CVS said at the March 5, 2024 investor meetings and webcast that its senior management team will reaffirm its previously announced full-year 2024 GAAP diluted earnings per share (EPS) guidance of at least $7.06 and Adjusted EPS guidance of at least $8.30.

2. 02

   The company also reaffirmed its previously announced full-year 2024 cash flow from operations guidance of at least $12.0 billion. It said Tom Cowhey, Chief Financial Officer, will provide an update on recent business trends during the webcast.

3. 03

   CVS said it adjusted full-year GAAP diluted EPS of at least $7.06 per share for the year ending December 31, 2024 to reach Adjusted EPS of at least $8.30, adding back amortization of intangible assets of 1.58, acquisition-related integration costs of 0.18, and a tax impact of non-GAAP adjustments of (0.52).

4. 04

   CVS said the acquisition-related integration costs it excludes from Adjusted EPS relate to its acquisitions of Signify Health, Inc. and Oak Street Health, Inc. It also said the webcast will be broadcast simultaneously on its Investor Relations website and that a replay will be archived for 1 years.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.